---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001047"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2023-06-29T23:59:59+00:00"
generated_at: "2026-06-13T14:45:14.525110+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aldeyra reports positive Phase 2 data for ADX-2191 in retinitis pigmentosa

## Summary
- Statistically significant improvement in best corrected visual acuity (P<0.0001) and low-light visual acuity (P=0.0001).
- Perimetry showed improved macular sensitivity (P<0.0001) and dark-adapted peripheral sensitivity (P<0.0001).
- Electroretinography time to response improved (P=0.02); no safety concerns identified.
- All 8 patients completed trial; ADX-2191 well tolerated with no serious adverse events.
- Company plans to discuss Phase 2/3 trial design with regulatory authorities.

## SEC filing metadata
- accession: 0001157523-23-001047
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2023-06-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000115752323001047/0001157523-23-001047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000115752323001047/a53436990.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001047
- JSON: https://secwatch.observer/filing/0001157523-23-001047.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.